Hormonal and molecular characterization of calcium oxalate stone formers predicting occurrence and recurrence

被引:4
作者
Elshal, Ahmed M. M. [1 ]
Shamshoun, Heba [3 ]
Awadalla, Amira [2 ]
Elbaz, Ramy [1 ]
Ahmed, Asmaa E. E. [2 ]
El-khawaga, Omali Y. Y. [3 ]
Shokeir, Ahmed A. A. [1 ,2 ]
机构
[1] Mansoura Univ, Urol & Nephrol Ctr, Dept Urol, Mansoura, Egypt
[2] Mansoura Univ, Ctr Excellence Genome & Canc Res, Urol & Nephrol Ctr, Mansoura, Egypt
[3] Mansoura Univ, Fac Sci, Mansoura, Egypt
关键词
Calcium oxalate; Androgen; Urolithiasis; Stone; KIDNEY-STONES; ANDROGEN RECEPTOR; SEX-HORMONES; RENAL STONE; TESTOSTERONE; UROLITHIASIS; PREVALENCE; RISK;
D O I
10.1007/s00240-023-01440-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The purpose of the study is to investigate the role of sex hormones, androgen receptors (ARs) and miRNA/CSF-1 in occurrence and recurrence of calcium oxalate (CaOx) renal urolithiasis. In this prospective study, 74 patients with CaOx stones; stone formers group (SFG) and 40 healthy subjects; control group were compared. SFG includes both de novo and recurrent cases. Steroid sex hormone plasma assay including testosterone, free testosterone, dihydrotestosterone, estradiol, and sex hormone binding globulin was analyzed. ARs, miRNA-185-5p and CSF-1 expression were compared between the groups. SFG showed significant higher ARs and miRNA-185-5p expression (3.7 +/- 1.3, 1.8 +/- 0.4, respectively) than control group (1 +/- 0.08 and 1 +/- 0.07, respectively) (p < 0.05). However, CSF-1 expression was significantly lower in stone formers than control group (0.4 +/- 0.19 vs 1 +/- 0.1, respectively) (p < 0.05). No differences were detected between de novo and recurrent SFG regarding sex hormones, AR, miRNA or CSF-1 expression. Our data suggest the important role of AR, miRNA and CSF-1 signaling in human nephrolithiasis pathogenesis.
引用
收藏
页数:7
相关论文
共 21 条
  • [1] Kidney Stone Disease: An Update on Current Concepts
    Alelign, Tilahun
    Petros, Beyene
    [J]. ADVANCES IN UROLOGY, 2018, 2018
  • [2] TRANSPORT OF STEROID-HORMONES - BINDING OF 21 ENDOGENOUS STEROIDS TO BOTH TESTOSTERONE-BINDING GLOBULIN AND CORTICOSTEROID-BINDING GLOBULIN IN HUMAN-PLASMA
    DUNN, JF
    NISULA, BC
    RODBARD, D
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 53 (01) : 58 - 68
  • [3] Fan J, 1999, J AM SOC NEPHROL, V10, pS376
  • [4] Gupta Kapil, 2016, Int J Appl Basic Med Res, V6, P241
  • [5] Is polycystic ovarian syndrome a risk factor for urolithiasis?
    Kaygusuz, Ikbal
    Karatas, Omer Faruk
    Kafali, Hasan
    Cimentepe, Ersin
    Unal, Dogan
    [J]. UROLITHIASIS, 2013, 41 (04) : 361 - 362
  • [6] DETERMINANT ROLE OF TESTOSTERONE IN THE PATHOGENESIS OF UROLITHIASIS IN RATS
    LEE, YH
    HUANG, WC
    CHIANG, H
    CHEN, MT
    HUANG, JK
    CHANG, LS
    [J]. JOURNAL OF UROLOGY, 1992, 147 (04) : 1134 - 1138
  • [7] Testosterone and Androgen Receptor in Human Nephrolithiasis
    Li, Jin-Yi
    Zhou, Tie
    Gao, XiaoFeng
    Xu, Chuanliang
    Sun, Yinghao
    Peng, Yonghan
    Chang, Zheng
    Zhang, Yuxi
    Jiang, Junyi
    Wang, Linhui
    Hou, Jianguo
    [J]. JOURNAL OF UROLOGY, 2010, 184 (06) : 2360 - 2363
  • [8] Androgen Receptor Enhances Kidney Stone-CaOx Crystal Formation via Modulation of Oxalate Biosynthesis & Oxidative Stress
    Liang, Liang
    Li, Lei
    Tian, Jing
    Lee, Soo Ok
    Dang, Qiang
    Huang, Chiung-Kuei
    Yeh, Shuyuan
    Erturk, Erdal
    Bushinsky, David
    Chang, Luke S.
    He, Dalin
    Chang, Chawnshang
    [J]. MOLECULAR ENDOCRINOLOGY, 2014, 28 (08) : 1291 - 1303
  • [9] Renal stone epidemiology in Rochester, Minnesota: An update
    Lieske, JC
    de la Vega, LSP
    Slezak, JM
    Bergstralh, EJ
    Leibson, CL
    Ho, KL
    Gettman, MT
    [J]. KIDNEY INTERNATIONAL, 2006, 69 (04) : 760 - 764
  • [10] Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
    Lin, Chien-Yu
    Liu, Jui-Ming
    Wu, Chun-Te
    Hsu, Ren-Jun
    Hsu, Wen-Lin
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (05)